No abstract

Hepatitis C virus (HCV) one-step diagnosis improves recovery in patients with active infection. However, patients with previous anti-HCV+ may be excluded. We aimed to identify and retrieve non-referred or lost-to-follow-up HCV-infected patients. All anti-HCV+ patients seen in our hospital between 2013 and 2018 were included.In the first phase, we identified anti-HCV+ patients who were not referred to the Gastroenterology Unit (GU) or lost-to-follow-up. In the second phase, recovered patients were invited for a one-step visit for liver evaluation. A total of 1330 anti-HCV+ patients were included: 21.7% had not been referred to GU, and 23.1% were lostto-follow-up. In the second phase, 49.6% of patients were contacted, and 92.8% attended a medical consultation: 62.7% had active infection, 92.2% were treated, and 86.5% achieved SVR (ITT). We concluded that screening microbiological data and referring unidentified patients with active HCV infection directly to specialists is an effective tool in achieving HCV microelimination.

No abstract

No abstract

No abstract

Resumen La gastroparesia es causa importante de morbilidad. La etiología más frecuente es la idiopática. Los síntomas son similares a la dispepsia, aunque el dolor abdominal superior es muy prevalente. El diagnóstico precisa demostrar vaciamiento gástrico retardado y descartar organicidad. El tratamiento incluye distintas modalidades farmacológicas, endoscópicas y quirúrgicas.

Patients with advanced chronic liver disease may be at increased risk of infection and/or severe course due to the cirrhosis-associated immune dysfunction. However, there is limited data linking chronic liver disease and Covid-19.Patients with cirrhosis are known to have abnormalities of immune function (immunodeficiency), as well as systemic inflammation, which is the pathophysiological hallmark of increased susceptibility to infection. Patients with cirrhosis are at a high risk of having a severe course of the influenza, including the development of organ failures. However, there is limited data on the course of Covid-19 in patients with chronic liver disease (CLD) and whether SARS-Cov2 can increase the risk of decompensation or development of acute-on-chronic liver failure (ACLF). Actual data indicates a prevalence (0-11%) of pre-existing liver conditions in patients with COVID-19.We present two cases of patients with decompensated liver disease that were evaluated for the SARS-Cov2 due to the new hospital policy of testing all patients who require hospital admission. One of them was asymptomatic, while the other presented mild respiratory symptoms. We believe that COVID-19 did not worsen liver function in our patients, and as such did not increase their risk of mortality or develop ACLF during admission.

No abstract